Drug
Sparc1316 Dose 1
Sparc1316 Dose 1: highest development phase Phase 1/2, developed by Sun Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Sun Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| SPARC1316 Dose 1 NCT02041221 | Phase 1/2 | Asthma |
Latest
No recent events.
Follow Sparc1316 Dose 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.